pyrvinium has been researched along with mdv 3100 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, S; Xiang, W | 1 |
| Adomat, H; Ban, F; Cherkasov, A; Dalal, K; Frewin, K; Leblanc, E; Li, H; Ma, D; Rennie, PS | 1 |
1 review(s) available for pyrvinium and mdv 3100
| Article | Year |
|---|---|
Therapeutic Strategies to Target the Androgen Receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
1 other study(ies) available for pyrvinium and mdv 3100
| Article | Year |
|---|---|
Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Line, Tumor; Cell Survival; Computer Simulation; Databases, Chemical; DNA; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Molecular Conformation; Molecular Docking Simulation; Morpholines; Mutation; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrvinium Compounds; Rats; Receptors, Androgen; Structure-Activity Relationship; Thiazoles; Thiophenes; Transcription, Genetic | 2014 |